Bifogade filer
SenzaGen’s subsidiary receives two orders within non-animal testing with a total value of SEK 2.4 million
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
SenzaGen’s subsidiary VitroScreen has received two orders from existing customers for non-animal testing. The total order value amounts to SEK 2.4 million, with the majority of revenues expected to be recognized in the second half of 2026. The orders indicate demand for VitroScreen’s offering from large global companies.
The projects will be carried out in close collaboration with the customers and form part of reoccurring business within VitroScreen’s customized testing services. Repeat orders demonstrate established partnerships and continued demand for the company’s services.
“These orders confirm demand for VitroScreen’s services from large global companies. Following a period in which we have implemented a number of measures to strengthen the subsidiary, it is encouraging to see clear signs of positive development. The orders provide a solid foundation for the remainder of the year, while we continue to further develop the business,” says Peter Nählstedt, CEO of SenzaGen.
VitroScreen’s test portfolio includes standardized and customized non-animal testing solutions based on human 3D tissue models and spheroids. The offering complements the Group’s test portfolio and broadens the ability to evaluate efficacy and toxicity with results that are more relevant than those obtained from animal testing.